Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
NCT06091748 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2025-06-03
Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Conditions
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
Interventions
- DRUG
-
68Ga-DOTATOC
Detection of somatostatin positive lesions in GEP-NETs
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-02-22
- Primary Completion
- 2025-11-01
- Completion
- 2025-11-01
Countries
- China
Study Locations
More Related Trials
-
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
NCT02078843 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors
NCT04318561 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
NCT02358018 ·Status: NO_LONGER_AVAILABLE
-
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
NCT04041882 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
NCT04040088 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
NCT03145857 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537 ·Status: COMPLETED ·Phase: PHASE2
-
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT04804371 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT01747096 ·Status: COMPLETED ·Phase: NA
-
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
NCT02174679 ·Status: NO_LONGER_AVAILABLE
-
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
NCT06056362 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
NCT02810600 ·Status: COMPLETED
-
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299 ·Status: COMPLETED
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
NCT02038738 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
NCT06455761 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Impact of Peptides and Chelators on Somatostatin Receptor Antagonists
NCT04491851 ·Status: UNKNOWN ·Phase: PHASE2
-
DOTATOC PET/CT for Imaging NET Patients
NCT03583528 ·Status: ACTIVE_NOT_RECRUITING
-
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
NCT02359500 ·Status: TERMINATED ·Phase: PHASE1
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT02608203 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1